However, Kohli et al. found that TTC3 may act like APOE in all members of a family with late-onset AD (LOAD), and TTC3 variants may contribute to LOAD risk, but may not initiate AD pathogenesis like APP (Kohli et al. 2016). This evidence concerns the gene TTC3 and Onset.